Quality of Life in Medium-Risk Patients Treated with TAVR vs SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) have demonstrated similar outcomes in symptomatic aortic stenosis patients (at high or intermediate risk) in terms of 5-year survival. When evaluating the quality of life (QoL) of these two treatment strategies in patients with high surgical risk, there were no significant differences at 5<a href="https://solaci.org/en/2024/05/10/quality-of-life-in-medium-risk-patients-treated-with-tavr-vs-savr/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR in Bicuspid Valves

Bicuspid aortic valve (BAV) disease affects 1%-2% of the population and manifests with severe aortic stenosis in the middle-aged.  It characterizes for a very different anatomy with more calcification than the tricuspid aortic valve. At present, surgical aortic valve replacement (SAVR) is the first treatment indication.  TAVR in this scenario has shown, in different studies,<a href="https://solaci.org/en/2024/05/07/tavr-in-bicuspid-valves/" title="Read more" >...</a>

Reinterventions in TAVR with Self-Expanding Valves

TAVR treatment of severe aortic stenosis is becoming more and more common, showing comparable evolution, or even superior in some studies when using the femoral approach, vs. surgical aortic valve replacement (SAVR). One of the current challenges is TAVR durability vs. SAVR. Even though 9 or 10 years has been deemed acceptable by current standards,<a href="https://solaci.org/en/2024/05/03/reinterventions-in-tavr-with-self-expanding-valves/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

SMART Trial: What is the Best Valve for Small Annuli?

Transcatheter aortic valve intervention (TAVI) has been shown beneficial over the years. However, a significant subgroup of patients with small aortic annulus, which make approximately one third of cases and have a higher incidence in women, face additional challenge, such as higher incidence of mismatch, reduced exercise capacity and shorter durability.  Self-expanding and balloon expandable<a href="https://solaci.org/en/2024/04/19/smart-trial-what-is-the-best-valve-for-small-annuli/" title="Read more" >...</a>

NOTION Trial: 10 Year Outcomes, TAVR vs. SAVR in Low Risk Patients

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR for treating inoperable patients, as well as high and intermediate risk patients.  The NOTION (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR or SAVR (surgical<a href="https://solaci.org/en/2024/03/22/notion-trial-10-year-outcomes-tavr-vs-savr-in-low-risk-patients/" title="Read more" >...</a>

Short-Term Outcomes of TAVR in Asymptomatic or Minimally Symptomatic Patients

Aortic valve replacement (AVR) is indicated for symptomatic aortic stenosis (AS), while close follow-up is recommended for asymptomatic patients, unless they have elevated aortic gradients, low ejection fraction, or abnormal stress tests. However, the optimal timing to perform AVR is uncertain, especially with recent evidence suggesting that patients with AS associated with signs of myocardial<a href="https://solaci.org/en/2024/02/21/short-term-outcomes-of-tavr-in-asymptomatic-or-minimally-symptomatic-patients/" title="Read more" >...</a>

TAVR in Low Risk Patients: 10 Year Evolution

The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR.  One of the fundamental questions that still remains unanswered revolves around device<a href="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...</a>

Coronary Artery Disease in TAVR: Unsolved Dilemma

Aortic stenosis shares risk factors with coronary artery disease (CAD), and its prevalence varies according to age, reaching approximately 50% or more in some registries. Deciding when to treat and the need for percutaneous intervention presents a challenge. It has been established that epicardial stenosis at proximal level, or the medial segment, requires intervention, especially<a href="https://solaci.org/en/2024/01/30/coronary-artery-disease-in-tavr-unsolved-dilemma/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Evolution of Bicuspid Valves at 12 Months

Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise.  TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>

Interventional Cardiology: The Most Read Articles of 2023

Discover the most read scientific articles on interventional cardiology of 2022 in our website. No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of<a href="https://solaci.org/en/2023/12/27/interventional-cardiology-the-most-read-articles-of-2023/" title="Read more" >...</a>